Recursion Pharmaceuticals Inc expected to post a loss of 42 cents a share - Earnings Preview

Recursion Pharmaceuticals

03/05/2024 16:08

* Recursion Pharmaceuticals Inc  RXRX.OQ   RXRX.O  is
expected
to show a rise in quarterly revenue when it reports  results on
May 9 for the period ending March 31 2024
    * The Salt Lake City Utah-based  company is expected to
report a
4.3% increase in revenue to $12.65 million from $12.13 million a
year ago, according to the mean estimate from 6 analysts, based
on LSEG data.
    * ​LSEG's mean analyst estimate for Recursion
Pharmaceuticals Inc
is for a loss of 42 cents per share. 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 5
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Recursion
Pharmaceuticals Inc is $12.50​, above​ its last closing price
of $8.79. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Jan. 1 0001   -0.46       -0.45      -0.42     Beat    6.4
 Sep. 30 0001  -0.38       -0.38      -0.43     Missed  -11.7
 Jun. 30 2023  -0.38       -0.37      -0.38     Missed  -1.5​
 Mar. 31 2023  -0.34       -0.35      -0.34     Beat    2.3
 ​​Dec.        -0.31       -0.29      -0.31     Missed  -6.9
 31 2022                                                
 Sep. 30 2022  -0.38       -0.38      -0.35     Beat    7.3​
 Jun. 30 2022  -0.38       -0.37      -0.38     Missed  -1.8
 Mar. 31 2022  0.12        0.10       -0.33     Missed  -430
 This summary was machine generated May 3 at 15:08 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)